Eureka Therapeutics to Present at 6th Annual Immuno-Oncology 360° Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that President and CEO Dr. Cheng Liu will be presenting at the 6^th Annual Immuno-Oncology 360° Conference (IO360°) in New York on February 27, 2020.

Dr. Liu will be presenting the use of Eureka’s novel antibody-TCR receptor (ARTEMIS^® T cell) that has been engineered with a proprietary human TCR-mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex on HCC cancer cells.

Presentation Details

Title: Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors

Speaker: Dr. Cheng Liu, President and CEO

Date: Thursday, February 27, 2020

Program: Cell & Gene Therapy Day, Track B

Time: 10:40 – 11:40 a.m. EST

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS^® AbTCR T cell receptor platform and E-ALPHA^® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of multiple solid and hematologic tumors. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.